158 related articles for article (PubMed ID: 3207527)
1. Relative bioavailability of controlled release morphine tablets (MST continus) in cancer patients.
Poulain P; Hoskin PJ; Hanks GW; A-Omar O; Walker VA; Johnston A; Turner P; Aherne GW
Br J Anaesth; 1988 Nov; 61(5):569-74. PubMed ID: 3207527
[TBL] [Abstract][Full Text] [Related]
2. The influence of the route of administration: a comparative study at steady state of oral sustained release morphine and morphine sulfate suppositories.
Du X; Skopp G; Aderjan R
Ther Drug Monit; 1999 Apr; 21(2):208-14. PubMed ID: 10217341
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy, safety and pharmacokinetics of a newly developed controlled release morphine sulphate suppository in patients with cancer pain.
Moolenaar F; Meijler WJ; Frijlink HW; Visser J; Proost JH
Eur J Clin Pharmacol; 2000 Jun; 56(3):219-23. PubMed ID: 10952476
[TBL] [Abstract][Full Text] [Related]
4. Single-dose and steady-state kinetics of morphine and its metabolites in cancer patients--a comparison of two oral formulations.
Hasselström J; Alexander N; Bringel C; Svensson JO; Säwe J
Eur J Clin Pharmacol; 1991; 40(6):585-91. PubMed ID: 1653145
[TBL] [Abstract][Full Text] [Related]
5. Plasma concentrations and renal clearance of morphine, morphine-3-glucuronide and morphine-6-glucuronide in cancer patients receiving morphine.
Somogyi AA; Nation RL; Olweny C; Tsirgiotis P; van Crugten J; Milne RW; Cleary JF; Danz C; Bochner F
Clin Pharmacokinet; 1993 May; 24(5):413-20. PubMed ID: 8504624
[TBL] [Abstract][Full Text] [Related]
6. Influences on serum concentrations of morphine, M6G and M3G during routine clinical drug monitoring: a prospective survey in 300 adult cancer patients.
Klepstad P; Dale O; Kaasa S; Zahlsen K; Aamo T; Fayers P; Borchgrevink PC
Acta Anaesthesiol Scand; 2003 Jul; 47(6):725-31. PubMed ID: 12803591
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients.
Wilkinson TJ; Robinson BA; Begg EJ; Duffull SB; Ravenscroft PJ; Schneider JJ
Cancer Chemother Pharmacol; 1992; 31(3):251-4. PubMed ID: 1464164
[TBL] [Abstract][Full Text] [Related]
8. Concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide in serum and cerebrospinal fluid following morphine administration to patients with morphine-resistant pain.
Goucke RC; Hackett PL; Ilett KF
Pain; 1994 Feb; 56(2):145-149. PubMed ID: 8008404
[TBL] [Abstract][Full Text] [Related]
9. Oral morphine in cancer pain: influences on morphine and metabolite concentration.
McQuay HJ; Carroll D; Faura CC; Gavaghan DJ; Hand CW; Moore RA
Clin Pharmacol Ther; 1990 Sep; 48(3):236-44. PubMed ID: 2401122
[TBL] [Abstract][Full Text] [Related]
10. Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain.
Quigley C; Joel S; Patel N; Baksh A; Slevin M
Palliat Med; 2003 Mar; 17(2):185-90. PubMed ID: 12701850
[TBL] [Abstract][Full Text] [Related]
11. Plasma morphine-3-glucuronide, morphine-6-glucuronide and morphine concentrations in patients receiving long-term epidural morphine.
Schneider JJ; Ravenscroft PJ; Cavenagh JD; Brown AM; Bradley JP
Br J Clin Pharmacol; 1992 Nov; 34(5):431-3. PubMed ID: 1467139
[TBL] [Abstract][Full Text] [Related]
12. Morphine and morphine-glucuronide concentrations in plasma and CSF during long-term administration of oral morphine.
van Dongen RT; Crul BJ; Koopman-Kimenai PM; Vree TB
Br J Clin Pharmacol; 1994 Sep; 38(3):271-3. PubMed ID: 7826830
[TBL] [Abstract][Full Text] [Related]
13. Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations.
Hasselström J; Säwe J
Clin Pharmacokinet; 1993 Apr; 24(4):344-54. PubMed ID: 8491060
[TBL] [Abstract][Full Text] [Related]
14. Concentrations of morphine and morphine metabolites in CSF and plasma during continuous subcutaneous morphine administration in cancer pain patients.
Wolff T; Samuelsson H; Hedner T
Pain; 1996 Dec; 68(2-3):209-16. PubMed ID: 9121807
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis.
Pauli-Magnus C; Hofmann U; Mikus G; Kuhlmann U; Mettang T
Nephrol Dial Transplant; 1999 Apr; 14(4):903-9. PubMed ID: 10328468
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine.
Stuart-Harris R; Joel SP; McDonald P; Currow D; Slevin ML
Br J Clin Pharmacol; 2000 Mar; 49(3):207-14. PubMed ID: 10718775
[TBL] [Abstract][Full Text] [Related]
17. Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration.
Wolff T; Samuelsson H; Hedner T
Pain; 1995 Aug; 62(2):147-154. PubMed ID: 8545139
[TBL] [Abstract][Full Text] [Related]
18. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy.
Holthe M; Klepstad P; Zahlsen K; Borchgrevink PC; Hagen L; Dale O; Kaasa S; Krokan HE; Skorpen F
Eur J Clin Pharmacol; 2002 Aug; 58(5):353-6. PubMed ID: 12185559
[TBL] [Abstract][Full Text] [Related]
19. Comparison of morphine slow release tablet (MST) and morphine sulphate solution (MSS) in the treatment of cancer pain.
Panich A; Charnvej L
J Med Assoc Thai; 1993 Dec; 76(12):672-6. PubMed ID: 7798818
[TBL] [Abstract][Full Text] [Related]
20. The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers.
Hoskin PJ; Hanks GW; Aherne GW; Chapman D; Littleton P; Filshie J
Br J Clin Pharmacol; 1989 Apr; 27(4):499-505. PubMed ID: 2719903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
